An award-winning County Durham company working in electric vehicle charging has been acquired by a global leader in the sector.
Consett-based Elmtronics – winner of the high growth and ambition award at the Durham, Sunderland and South Tyneside Business Awards in 2020 – has been acquired by EV charging company Mer, headquartered in Israel, to strengthen its position in the 海角视频 and “create the best and most customer-oriented EV charging experience”.
Elmtronics - which was singled out as a One to Watch in 2022 by The Journal and the BusinessLive website - specialises in electric car-charging points for homes, businesses and the public sector, designing, installing and maintaining electric vehicle-charging stations.
Read more : go here for more deals news
North East holiday park operator Parkdean Resorts has announced it has acquired a Yorkshire caravan transport company.
The Newcastle business, which has 67 parks around the 海角视频 including nine in the North East and Yorkshire, has snapped up Hanson European Caravan Transport Ltd.
Parkdean said the acquisition, made for an undisclosed sum, will facilitate the servicing of all of its resorts and ensure a closer relationship between the two companies.
North East pharmaceutical firm Shield Therapeutics has announced a deal worth up to £1m to pave the way for the sale of its lead drug in Canada.
Most Read
The Gateshead based company’s main drug, which treats iron deficiency anaemia, is now sold outside out Europe as Accrufer, having been originally launched in the 海角视频 six years ago under the Ferracru name.
The firm has now announced an exclusive licence agreement for Accrufer with KYE Pharmaceuticals Inc in Canada, which will see the Ontario based business take on all costs, both clinical and regulatory, to achieve marketing authorisation and commercialisation of the product in Canada. Shield, meanwhile, will be responsible for all manufacturing costs of goods sold in Canada.
Two Tyneside sport and exercise scientists who launched an app to improve employee wellbeing are set to ramp up development of the platform and create jobs, on the back of an £800,000 investment.
Dr Phill Bell and Dr Paul Smith have secured funds from the North East Venture Fund (NEVF), supported by the European Regional Development Fund and managed by Mercia, to fund the next stage of growth for the app, called One Wellbeing, which they devised to boost performance and wellbeing.
The pair will use the investment to further develop their platform as well as expand their Gateshead-based company ART Health Solutions , with the creation of 20 new jobs in the next two years.
Norwegian firm Wastefront AS has announced Technip Energies as its engineering, procurement and construction (EPC) partner for the build of its multimillion-pound recycling plant.
Wastefront AS , co-founded in Oslo three years ago by former Sunderland University student Christian A. Hvamstad, takes old tyres and turns them into useful commodities like liquid hydrocarbons and carbon black, which can then be reused by manufacturers.
Don’t miss
The innovative recycler announced plans to open its first waste tyre recycling plant at Port of Sunderland two years ago.
French company Technip Energies was selected following a competitive study phase that reviewed the earlier project development work.
Construction phase will start in the second quarter of this year and will be accompanied by Technip Energies until the plant’s start-up, expected to be in the first quarter of 2024.
Newcastle biotech business Iksuda Therapeutics has signed a technology-transfer deal with a Korean pharmaceutical firm which could be worth £730m.
The Newcastle Helix based firm's license and commercialisation agreement with LegoChem Biosciences (LCB) which will see the Daejeon-based company tap further into the Tyneside firm’s antibody-drug conjugate (ADC) technology.
ADCs target tumour cells and poisons them and Iksuda’s ADC programmes target tumours that currently have limited treatment options and high-relapse rates.
Under the terms of the agreement Iksuda Therapeutics will get exclusive rights to develop and market LCB’s cancer treatment drug, currently known as LCB14 in most countries, while LCB will keep the rights in China and Korea.